Welcome to our dedicated page for Rani Therapeutics Holdings news (Ticker: RANI), a resource for investors and traders seeking the latest updates and insights on Rani Therapeutics Holdings stock.
Rani Therapeutics Holdings, Inc. reports developments tied to its clinical-stage biotherapeutics platform for oral delivery of biologics and drugs. The company’s RaniPill® capsule technology is designed to deliver drug substances such as antibodies, proteins, peptides and oligonucleotides as an alternative to subcutaneous injection or intravenous infusion.
Recurring RANI news includes clinical and preclinical updates for RaniPill-based programs, including RT-114, a GLP-1/GLP-2 dual agonist program for obesity, and oral semaglutide work. Company updates also cover financial results, collaboration and license activity, private placement financing, manufacturing and supply-chain capabilities, pipeline prioritization, investor conference participation, and leadership or advisory appointments supporting platform and clinical strategy.
Rani Therapeutics announced the pricing of its initial public offering (IPO) of 6,666,667 shares of Class A common stock at $11.00 per share, aiming to raise approximately $73.3 million. The shares are set to start trading on the Nasdaq under the symbol 'RANI' on July 30, 2021, with the offering closing on August 3, 2021. The underwriters have a 30-day option to purchase up to 1,000,000 additional shares. This move bolsters Rani's development of the RaniPill capsule, a novel technology designed to replace injections with oral dosing of biologics.